NRx Pharmaceuticals Expands Its Reach in Neuropsychiatry with Acquisition of Kadima Institute

NRx Pharmaceuticals, through its subsidiary HOPE Therapeutics, has entered into a definitive agreement to acquire the Kadima Neuropsychiatry Institute, a move that underscores the company's commitment to advancing treatment options for central nervous system (CNS) disorders. Kadima, renowned for its innovative approaches in interventional psychiatry, offers a range of treatments including ketamine, Spravato, and transcranial magnetic stimulation (TMS), catering to conditions such as suicidal depression and PTSD. This acquisition not only brings a profitable clinic under the HOPE Therapeutics umbrella but also introduces Dr. David Feifel, Kadima's founder and a pioneer in interventional psychiatry, as HOPE's first Chief Medical Innovation Officer.

The acquisition is poised to serve as a clinical model for future HOPE clinics, leveraging Kadima's expertise and established protocols. This strategic move aligns with NRx Pharmaceuticals' broader mission to develop and commercialize novel therapeutics for CNS disorders, including its NMDA platform-based treatments. The company's pipeline includes NRX-101, an investigational therapy with FDA Breakthrough Therapy designation for suicidal treatment-resistant bipolar depression and chronic pain, and NRX-100 (IV ketamine), which is currently under New Drug Application review for suicidal depression.

For further details on the acquisition and NRx Pharmaceuticals' innovative treatments, visit https://ibn.fm/T1WlB. Additional information about NRx Pharmaceuticals and its groundbreaking work in CNS disorders can be found at https://www.nrxpharma.com/.